Loading stock data…
MANE
$107.14+3.24 (+3.12%)
Pre-Market$107.50+0.36 (+0.34%)· Last close May 13
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$107.14
Potential Downside
0%
Whystock Fair Value$107.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$126.00+17.6%
Range$120.00 – $138.00
Fundamentals
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.73%
Volume
Today's trading volume
314,097
Recent News
Citi Remains Bullish on Veradermics, Incorporated (MANE)
Veradermics, Incorporated (NYSE:MANE) is one of the best performing healthcare stocks so far in 2026. On April 27, Citi lifted the price target on Veradermics, Incorporated (NYSE:MANE) to $120 from $85, reaffirming a Buy rating on the shares. The rating update came after the company announced positive topline results from Part A of its Phase […]
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill
Veradermics reported “positive top line results” from Part A of its Phase II/III 302 trial evaluating VDPHL01, an oral extended-release minoxidil tablet, in men with mild to moderate pattern hair loss. On a conference call, CEO Dr. Reid Waldman said the randomized, double-blind, placebo-controlled s
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01
Veradermics Incorporated (NYSE:MANE) is one of the small-cap stocks that are on fire right now. On April 27, Veradermics announced positive topline results from its Phase 2/3 “302” clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation for male pattern hair loss. The study, which included 519 participants, met all primary and key secondary […]
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
Veradermics Inc. announced on Monday that its novel oral formulation, VDPHL01, achieved positive results in a Phase 2/3 trial for pattern hair loss. Hair Growth Gains And Patient Response Metrics The development positions the treatment as a potential first FDA-approved oral pill for hair loss in nearly 30 years. Hair Growth Increase: 30.3 hairs/cm² (once daily) and 33.0 hairs/cm² (twice daily) compared to 7.3 hairs/cm² for placebo. Patient Improvement: 79.3% (once daily) and 86.0% (twice daily)
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
The major averages were broadly lower amid stalled peace negotiations between the U.S. and Iran as well as new escalation in the Strait of Hormuz. Investors are also balancing continued strength in corporate earnings and AI-driven optimism with rising geopolitical tension and macro uncertainty. Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart I